Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2008
10/14/2008CA2168584C A method for sensitization of cancer cells for killer cell mediated lysis
10/09/2008WO2008122039A2 Selenocysteine mediated hybrid antibody molecules
10/09/2008WO2008121941A1 Prodrugs of triciribine and triciribine phosphate
10/09/2008WO2008121876A2 Non-fucosylated antibodies
10/09/2008WO2008121821A1 Treatment of hodgkins lymphoma
10/09/2008WO2008121742A2 Inhibitors of bruton's tyrosine kinase
10/09/2008WO2008121687A2 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
10/09/2008WO2008121476A1 Biologically active taxane analogs and methods of treatment by oral administration
10/09/2008WO2008121467A2 Combination therapy for treating cancer
10/09/2008WO2008121126A1 Non-peptidic molecules for detecting and treating tumors
10/09/2008WO2008121102A2 Hedgehog signaling pathway antagonist cancer treatment
10/09/2008WO2008121016A1 Oncological disease treating method
10/09/2008WO2008120815A1 Targeting agent for cancer cell or cancer-associated fibroblast
10/09/2008WO2008120812A1 Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
10/09/2008WO2008120711A1 Tamibarotene capsule preparation
10/09/2008WO2008120690A1 Optically active organic acid-bridged binuclear platinum (ii) complexes
10/09/2008WO2008120653A1 Indoledione derivative
10/09/2008WO2008120235A1 Novel benzophenone hybrids as potential anticancer agents and a process for the preparation thereof
10/09/2008WO2008120206A1 Water soluble opuntia extracts for the inhibition of alpha-1-adrenergic receptors
10/09/2008WO2008120202A2 Antibodies, methods and kits for diagnosing and treating melanoma
10/09/2008WO2008120101A2 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
10/09/2008WO2008120098A2 Peptide prodrugs
10/09/2008WO2008120093A1 Sulfonamides and pharmaceutical compositions thereof
10/09/2008WO2008120004A1 Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
10/09/2008WO2008119790A2 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes
10/09/2008WO2008119771A2 Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors
10/09/2008WO2008119741A2 3-imidazolyl-indoles for the treatment of proliferative diseases
10/09/2008WO2008119694A1 Benzimidazole cannabinoid agonists
10/09/2008WO2008119567A2 Cross-species-specific cd3-epsilon binding domain
10/09/2008WO2008119493A1 Composition of labeled and non-labeled monoclonal antibodies
10/09/2008WO2008119260A1 A medicinal composition of carmustine, preparation method and application
10/09/2008WO2008119258A1 A recombinant adenovirus useful for treating malignancy overexpressing proto-oncogene neu/erbb2
10/09/2008WO2008119176A1 Amidation process for the preparation of cathepsin k inhibitors
10/09/2008WO2008100805A3 Anti-robo4 antibodies and uses therefor
10/09/2008WO2008100622A3 Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
10/09/2008WO2008098917A3 Novel antibodies against igf-ir
10/09/2008WO2008084081A3 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
10/09/2008WO2008070354A3 5- and 6- substituted benzimidazole thiophene compounds
10/09/2008WO2008057252A3 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
10/09/2008WO2008049105A3 Sulfamoyl-containing derivatives and uses thereof
10/09/2008WO2008041933A3 Rna interference against wrap53 to treat hyperproliferative diseases
10/09/2008WO2008032105A3 Flavonoid derivatives and their uses
10/09/2008WO2008024304A3 Compounds for treatment of proliferative disorders
10/09/2008WO2008022295A3 Prlr-specific antibody and uses thereof
10/09/2008WO2008022002A3 2-amido-4-isoxazolyl thiazole compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
10/09/2008WO2008019061A3 Anti-il-6 monoclonal antibodies and uses thereof
10/09/2008WO2008007262B1 Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity
10/09/2008WO2007100566A3 Use of dha and ara in the preparation of a composition for regulating gene expression
10/09/2008WO2007095729A8 Cytotoxicity mediation of cells evidencing surface expression of cd63
10/09/2008WO2007092721A8 Vitamin d analog: rak, methods and uses thereof
10/09/2008WO2007089367A3 Use hedgehog kinase antagonists to inhibit hedgehog signaling and to treat cancer
10/09/2008US20080249320 Luminacin analogs and uses thereof
10/09/2008US20080249298 use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
10/09/2008US20080249179 histone deacetylase (HDAC) inhibitor useful in selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells; have a high bioavailability and gives high blood levels of the active compounds over a long time
10/09/2008US20080249162 ATPase inhibitors; anticancer agents; synthesis and chemical intermediates thereto
10/09/2008US20080249157 Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof
10/09/2008US20080249148 For contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus
10/09/2008US20080249147 Emulsion-Stabilized Preparation
10/09/2008US20080249124 Conjugate linkage is removable upon administration; 41-Desmethoxyrapamycin-L-wortmannin; antineoplastic agents
10/09/2008US20080249123 Wortmannin-rapamycin conjugate and uses thereof
10/09/2008US20080249121 Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agent
10/09/2008US20080249119 Nucleosiding a protected cytosine with a protected hexose, deprotecting to obtain gemcitabine; administering as produgs; cancers of the lungs, ovaries, pancreas and bladder; cost efficiency; simplification
10/09/2008US20080249118 diagnosing prostate carcinoma by determining the methylation degree in the genomic locus of a gene selected from the group consisting of 14-3-3 sigma , DDB2, GPX3, GSTM1, SFRP1, DKK3, p57/KIP2, COX-21PTGS2, HPGD and combinations thereof in a sample, wherein a hypermethylation is indicative of cancer
10/09/2008US20080249115 small molecule, non-peptide, modulators (e.g., antagonists or agonists) of peptide hormones; treating low blood pressure or an eating disorder
10/09/2008US20080249112 Antiproliferavtive agents; small molecule inhibitors of KSP(kinesin-related proteins); N-(3-aminopropyl)-N-[1-(3-benzyl-4-oxo-6,7,8 ,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-2-yl)propyl]-4-bromobenzamide
10/09/2008US20080249104 Salt Forms of 4- (4-Methylpiperazin-1-Ylmethyl) -N- [4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl]- Benzamide
10/09/2008US20080249100 N-[2-(2-{[(3,4-dichlorophenyl)methyl]amino}-7-oxo-8-hydropteridin-8-yl)ethyl]carboxamides; antidiabetic, anticholesterol, anticarcinogenic, antiischemic, hypotensive agents; obesity, stroke
10/09/2008US20080249098 peripheral benzodiazepine receptors; 7-fluoro-N,N,5-trimethyl-4-oxo-3-(pyridin-2-yl)-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-carboxamide; for the treatment of various types of peripheral neuropathies, amyotrophic lateral sclerosis
10/09/2008US20080249090 1-(4-(1H-pyrrol-1-yl)phenyl)-3-(2-aminoquinazolin-6-yl)-4-methylpyridin-2(1H)-one; modulators of kinase enzymes such as c-kit, and useful for the regulation of autoimmune disease(s), allergies, asthma, cancer and the like
10/09/2008US20080249085 for treating cell proliferative diseases; maytansinoid analogs; with lower systemic toxicity, improved pharmacokinetic profile, and better clinical activity; inhibiting fungal growth; compounds can target tubulin, Heat Shock Protein-90
10/09/2008US20080249083 isolated nucleic acids coding for novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs); isoenzymes; useful for the discovery of new therapeutic agents, for measuring cyclase activity; Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, Down Syndrome, Huntington's disease
10/09/2008US20080249079 Pyrimidine Derivatives As Kinase Modulators and Method of Use
10/09/2008US20080249036 Antagonist Against Tolerance to Anticancer Drugs
10/09/2008US20080249026 PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS
10/09/2008US20080249025 Peptide fragments of p21; antiproliferative agents
10/09/2008US20080249013 Immunogenic fragment of a Cripto fusion protein that is reactive with an antibody or T-cell that reacts with a given polypeptide sequence; polynucleotides, expression vectors, host cells, T-cell lines; diganosis, prevention, treatment of lung, colon, colorectal and breast cancers
10/09/2008US20080249009 ApM-1 and related proteins to influence partitioning of dietary lipids between liver and peripheral tissues; reduce free fatty acids in obese individuals; decrease body weight; atherosclerosis; insulin resistance; hypertension, microangiopathic lesions
10/09/2008US20080249008 Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
10/09/2008US20080249005 Use of Dm43 and Its Fragments as Matrix Metalloproteinases Inhibitor
10/09/2008US20080249004 Method of Modulating Cell Survival, Differentiation and/or Synaptic Plasticity
10/09/2008US20080249001 Agents that alleviate side-effects caused by chemotherapy agents
10/09/2008US20080248566 Matriptase, a serine protease and its applications
10/09/2008US20080248134 antiproliferative agents for inducing p53 expression and decreasing survivin expression in cells; multidrug resistant proliferative disorders; synergistic use with other chemotherapeutic agents like temozolomide
10/09/2008US20080248129 Compounds and methods for promoting cellular health and treatment of cancer
10/09/2008US20080248097 Polymeric micelles for combination drug delivery
10/09/2008US20080248096 Delivering, via small particle aerosol, aqueous dispersions of anti-cancer drugs in liposomes or lipid complexes to respiratory tract of an individual in need of such treatment
10/09/2008US20080248095 Delivering, via small particle aerosol, aqueous dispersions of anti-cancer drugs in liposomes or lipid complexes to respiratory tract of an individual in need of such treatment
10/09/2008US20080248094 Vaccine adjuvant properties of lipsomes formed at elevated temperatures from the polar chloroform extractable lipids from mycobacterium bovis
10/09/2008US20080248093 pH sensitive prodrugs of 2,6-diisopropylphenol
10/09/2008US20080248092 Formulations of Water Insoluble or Poorly Water Soluble Drugs in Lipidated Glycosaminoglycan Particles and Their Use for Diagnostic and Therapy
10/09/2008US20080248077 Anastrozole continuously released from polylactide or poly(lactide-co-glycolide) co-polymer implant over 10 day period in aqueous physiological environment; drug incorporated in microparticle formulations and monolithic implant formulations; breast cancer
10/09/2008US20080248054 Regulation of Mink in Thymocytes and T Lymphocytes
10/09/2008US20080248053 Antibody-drug conjugates; Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF); cancer; autoimmune diseases
10/09/2008US20080248051 Monomethylvaline compounds capable of conjugation to ligands
10/09/2008US20080248049 Using endothelial growth factor specific monoclonal antibody for treatment and prevention of leukemia; immunotherapy
10/09/2008US20080248046 Death domain containing receptor 5
10/09/2008US20080248042 Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
10/09/2008US20080248036 Treatment with anti-vegf antibodies
10/09/2008US20080248033 VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
10/09/2008US20080248029 Prevention and treatment of amyloidogenic diseases
1 ... 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 ... 2211